The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease

Expert Review of Molecular Diagnostics

Volumn 15, Issue 12, 2015, Pages 1577-1588

  Bank, Ingrid E M ^a,b   Timmers, Leo ^a,b,c   Gijsberts, Crystel M ^a,b   Zhang, Ya Nan ^d,e   Mosterd, Arend ^f   Wang, Jiong Wei ^d,e   Chan, Mark Y ^c   De Hoog, Vince ^a,b   Lim, Sai Kiang ^g   Sze, Siu Kwan ^h   Lam, Carolyn S P ⁱ   De Kleijn, Dominique P V ^a,b,d,e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^f MEANDER MEDICAL CENTER   (Netherlands)

^g INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^h NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

ⁱ DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

biomarker; cardiovascular disease; flow cytometry; microparticles; Plasma extracellular vesicles; vesicle content; vesicle counts

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; PLASMA PROTEIN;

BLOOD SAMPLING; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL SURVIVAL; DIAGNOSTIC VALUE; EXOSOME; FLOW CYTOMETRY; HUMAN; LIMIT OF DETECTION; LIPID BILAYER; MEMBRANE MICROPARTICLE; MULTIVESICULAR BODY; PROGNOSIS; REVIEW; BLOOD; CARDIOVASCULAR DISEASES; PROCEDURES; PROTEOMICS;

BIOMARKERS; CARDIOVASCULAR DISEASES; EXTRACELLULAR VESICLES; FLOW CYTOMETRY; HUMANS; MICRORNAS; PROGNOSIS; PROTEOMICS;

EID: 84949538323     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.1109450     Document Type: Review

References (71)

1. WHO | Cardiovascular diseases (CVDs). World Health Organization. [cited 2015 Jun 1]. Available from: http://www.who. int/mediacentre/factsheets/fs317/en/
2. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. World Heal Organ. 2011.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3 (11):2011-2030.
4. Tushuizen ME, Diamant M, Sturk A, et al. Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe? Arterioscler Thromb Vasc Biol. 2011;31:4-9.
5. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: A potential prognostic marker for atherosclerotic vascular disease. Hypertension. 2006;48 (2):180-186.
6. Loyer X, Vion AC, Tedgui A, et al. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res. 2014;114:345-353.
7. Owens AP, MacKman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108(10):1284-1297.
8. Diamant M, Tushuizen ME, Sturk A, et al. Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest. 2004;34:392-401.
9. Cervio E, Barile L, Moccetti T, et al. Exosomes for intramyocardial intercellular communication. Stem Cells Int [Internet]. 2015;2015:1-10. Available from: http://www.hindawi.com/journals/ sci/2015/482171/
10. Amabile N, Cheng S, Renard JM, et al. Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study. Eur Heart J [Internet]. 2014;1-8. Available from: http://www.ncbi.nlm.nih. gov/pubmed/24742886
11. Fleury A, Martinez MC, Le Lay S. Extracellular vesicles as therapeutic tools in cardiovascular diseases. Front Immunol. 2014;5(Aug):1-8.
12. Kormelink TG, Arkesteijn GJA, Nauwelaers FA, et al. Prerequisites for the analysis and sorting of extracellular vesicle subpopulations by high-resolution flow cytometry. Cytometry A [Internet]. 2015. Available from: http://www.ncbi. nlm.nih.gov/pubmed/25688721
13. Van Der Pol E, Van Gemert MJC, Sturk A, et al. Single vs. swarm detection of microparticles and exosomes by flow cytometry. J Thromb Haemost. 2012;10 (5):919-930.
14. Headland SE, Jones HR, D'Sa ASV, et al. Cutting-edge analysis of extracellular microparticles using ImageStream(X) imaging flow cytometry. Sci Rep [Internet]. 2014;4:5237. Available from: http://www.pubmedcentral.nih.gov/arti clerender.fcgi?artid=4050385&tool= pmcentrez&rendertype=abstract
15. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation. 2000;101(8):841-843.
16. Bernal-Mizrachi L, Jy W, Jimenez JJ, et al., et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J. 2003;145(6):962-970.
17. Matsumoto N, Nomura S, Kamihata H, et al. Increased level of oxidized LDLdependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost. 2004;91(1):146-154.
18. Morel O, Pereira B, Averous G, et al. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. Atherosclerosis. 2009;204:636-641.
19. Nakata T, Hashimoto A, Hase M, et al. Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology [Internet]. 2003 [cited 2014 May 1];99(2):96-104. Available from: http://www.karger.com/doi/10. 1159/000069726
20. Hu-S-S, Zhang H-G, Zhang Q-J, et al. Small-size circulating endothelial microparticles in coronary artery disease. Plos One [Internet]. 2014;9(8):e104528. Available from: http://dx.plos.org/10. 1371/journal.pone.0104528
21. Montoro-García S, Shantsila E, Tapp LD, et al. Small-size circulating microparticles in acute coronary syndromes: relevance to fibrinolytic status, reparative markers and outcomes. Atherosclerosis. 2013;227(2):313-322.
22. Skeppholm M, Mobarrez F, Malmqvist K, et al. Platelet-derived microparticles during and after acute coronary syndrome. Thromb Haemost. 2012;1122-1129.
23. Chironi G, Simon A, Hugel B, et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol. 2006;26 (12):2775-2780.
24. Jayachandran M, Litwiller RD, Owen WG, et al. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol. 2008;295(3):H931-8.
25. Koga H, Sugiyama S, Kugiyama K, et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2005;45(10):1622-1630.
26. Jung C, Sörensson P, Saleh N, et al. Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with STelevation myocardial infarction. Atherosclerosis [Internet]. 2012;221 (1):226-231. Elsevier Ireland Ltd. DOI:10.1016/j. atherosclerosis.2011.12.025.
27. Simak J, Gelderman MP, Yu H, et al. Circulating endothelial microparticles in acute ischemic stroke: A link to severity, lesion volume and outcome. J Thromb Haemost. 2006;4(6):1296-1302.
28. Lee YJ, Jy W, Horstman LL, et al., et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res. 1993;72(4):295-304.
29. Van Der Zee PM, Biró E, Ko Y, et al. Pselectin-and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem. 2006;52 (4):657-664.
30. Choudhury A, Chung I, Blann AD, et al. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to P-selectin and antithrombotic therapy. Chest. 2007;131(3):809-815.
31. Chirinos JA, Heresi GA, Velasquez H, et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol. 2005;45(9):1467-1471.
32. Walenta K, Schwarz V, Schirmer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J. 2012;33(12):1469-1479.
33. Preston RA, Jy W, Jimenez JJ, et al., et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 2003;41(2):211-217.
34. Sabatier F, Darmon P, Hugel B, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes. 2002;51 (9):2840-2845.
35. Nomura S, Shimizu M. Clinical significance of procoagulant microparticles. J Intensive Care [Internet]. 2015;3(1):1-11. Available from: http://www.jintensive care.com/content/3/1/2
36. Giannopoulos G, Oudatzis G, Paterakis G, et al. Red blood cell and platelet microparticles in myocardial infarction patients treated with primary angioplasty. Int J Cardiol [Internet]. 2014;176 (1):145-150. Available from: http://www. ncbi.nlm.nih.gov/pubmed/25062560
37. Huisse MG, Ajzenberg N, Feldman L, et al. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction. Thromb Haemost. 2009;101 (4):734-740.
38. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol [Internet]. 2012 Oct 16 [cited 2014 Apr 28];60 (16):1581-1598. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/ 22958960
39. Augustine D, Ayers LV, Lima E, et al. Dynamic release and clearance of circulating microparticles during cardiac stress. Circ Res. 2014;114(1):109-113.
40. Lacroix R, Judicone C, Poncelet P, et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J Thromb Haemost. 2012;10 (3):437-446.
41. Berezin AE, Kremzer AA, Samura TA, et al. Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus. J Endocrinol Invest [Internet]. 2015;38(8):865-874. Available from: http://www.ncbi.nlm.nih. gov/pubmed/25916429
42. Jersmann HP. Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells. Immunol Cell Biol. 2005;83 (5):462-467.
43. Nozaki T, Sugiyama S, Koga H, et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol [Internet]. 2009;54(7):601-608. American College of Cardiology Foundation. DOI:10.1016/j. jacc.2009.05.022.
44. Sinning JM, Losch J, Walenta K, et al. Circulating CD31 +/Annexin V + microparticles correlate with cardiovascular outcomes. Eur Heart J. 2011;32 (16):2034-2041.
45. Schiro A, Wilkinson FL, Weston R, et al. Endothelial microparticles as conveyors of information in atherosclerotic disease. Atherosclerosis. 2014;45:295-302.
46. Berezin AE, Kremzer AA, Samura TA, et al. Predictive value of apoptotic microparticles to mononuclear progenitor cells ratio in advanced chronic heart failure patients. J Cardiol [Internet]. 2014;65 (5):403-411. Japanese College of Cardiology. DOI:10.1016/j. jjcc.2014.06.014.
47. Wang K, Zhang S, Weber J, et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010;38(20):7248-7259.
48. De Hoog VC, Timmers L, Schoneveld AH, et al. Serum extracellular vesicle protein levels are associated with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care [Internet]. 2013 Mar [cited 2014 May 1];2(1):53-60. Available from: http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid= 3760575&tool=pmcentrez&rendertype= abstract
49. Kanhai DA, Visseren FLJ, Van Der Graaf Y, et al. Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. Int J Cardiol [Internet]. 2013;168 (3):2358-2363. Elsevier Ireland Ltd. DOI:10.1016/j.ijcard.2013.01.231.
50. Chambers AG, Percy AJ, Simon R, et al. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum. Expert Rev Proteomics [Internet]. 2014;11(2):137-148. Available from: http://www.ncbi. nlm.nih.gov/pubmed/24476379
51. Kanhai DA, De Kleijn DPV, Kappelle LJ, et al. Extracellular vesicle protein levels are related to brain atrophy and cerebral white matter lesions in patients with manifest vascular disease: the SMARTMR study. BMJ Open [Internet]. 2014;4 (1):e003824. Available from: http://www. pubmedcentral.nih.gov/articlerender.fcgi? artid=3902438&tool=pmcentrez&render type=abstract
52. Kranendonk MEG, De Kleijn DPV, Kalkhoven E, et al. Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease. Cardiovasc Diabetol [Internet]. 2014;13:37. Available from: http://www. pubmedcentral.nih.gov/articlerender.fcgi? artid=3918107&tool=pmcentrez&render type=abstract
53. Datta A, Chen CP, Sze SK. Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma. PLoS One. 2014;9(4):e94663.
54. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469(7330):336-342.
55. Zampetaki A, Willeit P, Drozdov I, et al. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res. 2012;93:555-562.
56. Zeller T, Keller T, Ojeda F, et al. Assessment of microRNAs in patients with unstable angina pectoris. Eur Heart J [Internet]. 2014 Aug 14 [cited 2014 Sep 11];35(31):2106-2114. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 24727883
57. Oerlemans MIFJ, Mosterd A, Dekker MS, et al. Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Mol Med [Internet]. 2012 Nov [cited 2014 Apr 29];4(11):1176-1185. Available from: http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid= 3494874&tool=pmcentrez&rendertype= abstract
58. Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106(6):1035-1039.
59. Badrnya S, Baumgartner R, Assinger A. Smoking alters circulating plasma microvesicle pattern and microRNA signatures. Thromb Haemost. 2014;112 (1):128-136.
60. Jansen F, Yang X, Proebsting S, et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc [Internet]. 2014;3(6):e001249-e001249. Available from: http://jaha.ahajournals.org/cgi/doi/ 10.1161/JAHA.114.001249
61. Hamm CW, Bassand J-P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevatio. Eur Heart J [Internet]. 2011 Dec [cited 2014 May 1];32(23):2999-3054. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 21873419
62. Mcmurray JJV, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail. 2012;14(8):803-869.
63. Rothstein L, Jickling GC. Ischemic stroke biomarkers in blood. Biomark Med [Internet]. 2013;7(1):37-47. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/23387483
64. Mora S, Wenger NK, DeMicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012;125:1979-1987.
65. Exosome Diagnostics Announces Data Demonstrating ExoIntelliScoreTM Prostate Accurately Predicted Gleason Score, Pathologic Stage and Tumor Volume in Patients with Prostate Cancer [Internet]. Available from: http://www. exosomedx.com/news-events/pressreleases/ exosome-diagnostics-announcesdata-demonstrating-exointelliscoretmprostate
66. Witwer KW, Buzás EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles [Internet]. 2013;2:1-25. Available from: http://www.pubmedcentral.nih.gov/arti clerender.fcgi?artid=3760646&tool= pmcentrez&rendertype=abstract
67. Gijsberts CM, Seneviratna A, De Carvalho LP, et al. Ethnicity modifies associations between cardiovascular risk factors and disease severity in parallel Dutch and Singapore coronary cohorts. Plos One [Internet]. 2015;10 (7):e0132278. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/ 26147693
68. Bank IE, Dekker MS, Hoes AW, et al. Suspected acute coronary syndrome in the emergency room: limited added value of heart type fatty acid binding protein point of care or ELISA tests: the FAME-ER (Fatty Acid binding protein in myocardial infarction evaluation in the emergency room) study. Eur Heart J Acute Cardiovasc Care. 2015.
69. Howard DPJ, Van Lammeren GW, Rothwell PM, et al. Symptomatic carotid atherosclerotic disease: correlations between plaque composition and ipsilateral stroke risk. Stroke. 2015;46 (1):182-189.
70. Lam CSP, Anand I, Zhang S, et al. Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. Eur J Heart Fail. 2013;15(8):928-936.
71. Chin CD, Linder V, Sia SK. Commercialization of microfluidic pointof-care diagnostic devices. Lab Chip. 2012;12:2118.